Bausch Health Companies Inc
TSX:BHC

Watchlist Manager
Bausch Health Companies Inc Logo
Bausch Health Companies Inc
TSX:BHC
Watchlist
Price: 6.22 CAD -4.31% Market Closed
Market Cap: 2.3B CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one BHC stock under the Base Case scenario is 113.72 CAD. Compared to the current market price of 6.22 CAD, Bausch Health Companies Inc is Undervalued by 95%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BHC Relative Value
Base Case
113.72 CAD
Undervaluation 95%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.2
P/S
P/S
Price to Sales
0.2
vs History
98
vs Industry
89
Median 3Y
0.3
Median 5Y
0.4
Industry
2.4
Forward
0.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.3
Industry
20.9
Forward
1
More Details
1
P/OCF
P/OCF
Price to OCF
1
vs History
79
vs Industry
52
Median 3Y
1.9
Median 5Y
3
Industry
15.9
More Details
2.7
P/FCFE
P/FCFE
Price to FCFE
2.7
vs History
36
vs Industry
36
Median 3Y
1.1
Median 5Y
1.2
Industry
23.7
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.1
Industry
2
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
93
vs Industry
48
Median 3Y
2.8
Median 5Y
2.8
Industry
2.6
Forward
2.2
More Details
3.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.2
vs History
93
vs Industry
60
Median 3Y
3.9
Median 5Y
4
Industry
5
More Details
7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7
vs History
93
vs Industry
42
Median 3Y
8.2
Median 5Y
8.4
Industry
12.4
Forward
6.1
More Details
11.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.8
vs History
93
vs Industry
35
Median 3Y
15.7
Median 5Y
16.4
Industry
15.9
Forward
6.3
More Details
13.6
EV/OCF
EV/OCF
Enterprise Value to OCF
13.6
vs History
74
vs Industry
32
Median 3Y
16.9
Median 5Y
21.4
Industry
14.2
More Details
17.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.9
vs History
74
vs Industry
25
Median 3Y
23.3
Median 5Y
27.2
Industry
17.6
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
90
vs Industry
63
Median 3Y
0.9
Median 5Y
0.9
Industry
1.8
More Details

Multiples Across Competitors

BHC Competitors Multiples
Bausch Health Companies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Bausch Health Companies Inc
TSX:BHC
2.3B CAD 0.2 -41.3 7 11.8
US
Eli Lilly and Co
NYSE:LLY
689.1B USD 14.2 62.5 33.7 36.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
369.2B USD 4.1 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20.1 13.2 15.1
CH
Roche Holding AG
SIX:ROG
209B CHF 3.5 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
183.2B CHF 4.2 17.2 10.2 13.6
UK
AstraZeneca PLC
LSE:AZN
162.7B GBP 4 28 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
193.7B USD 3 11.2 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
117.5B EUR 1.3 9.3 5.1 6
P/E Multiple
Earnings Growth PEG
CA
Bausch Health Companies Inc
TSX:BHC
Average P/E: 23.8
Negative Multiple: -41.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
62.5
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.3
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Bausch Health Companies Inc
TSX:BHC
Average EV/EBITDA: 394.3
7
10%
0.7
US
Eli Lilly and Co
NYSE:LLY
33.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.7
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Bausch Health Companies Inc
TSX:BHC
Average EV/EBIT: 1 697.8
11.8
27%
0.4
US
Eli Lilly and Co
NYSE:LLY
36.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.1
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6
14%
0.4

See Also

Summary
BHC intrinsic value, competitors valuation, and company profile.
DCF Valuation
BHC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BHC stock valuation using valuation multiples.
Wall Street Estimates
BHC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BHC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.